Articles

In 2010, Dr Thomas Frieden, director of the Centers for Disease Control and Prevention (CDC), chose the 6 original health priorities that he would call “winnable battles.” Read More ›

The optimal dosing of pomalidomide in the treatment of multiple myeloma has not been established. Yale University investigators compared continuous and intermittent dosing regimens, and while the intermittent schedule was associated with more toxicity, they concluded that it is preferable... Read More ›

Honesty is not always a bad thing: I am also the person who tells you that you have something in your teeth, yanks toilet paper off your foot, or pulls out that skirt, which you somehow tucked into your panty hose, before you leave the restroom. Read More ›

The St. Jude Crosson Comprehensive Cancer Center, located in Fullerton, California, is part of the St. Joseph Health System. The cancer center was established in 1998 and includes the Ann G. Fetters Diagnostic Imaging Center, the Fred A. Jordan Family Radiation Oncology Center, and the Kathryn T. McCarty Breast Center. Read More ›

In this issue of The Oncology Nurse-APN/PA (TON), we discuss some of the “personal” situations we may confront as healthcare professionals. Read More ›

May 5th is Melanoma Monday, as designated by the American Academy of Dermatology. Read More ›

As a 7-year breast cancer survivor, my primary feeling most of the time is awe and gratitude that I’m still here. I can savor life’s small moments and big events, from sipping a piping hot tall dark roast to celebrating my dear friend’s 50th by dancing my you-know-what off! Read More ›

Younger, thinner, nondiabetic men were more likely to gain weight on androgen deprivation therapy (ADT) than older men with comorbidities. Read More ›

The Cancer Genome Atlas (TCGA) project now includes a recently reported comprehensive molecular characterization of muscle-invasive urothelial bladder carcinoma... Read More ›

Building on the theme of appropriate use of procedures and treatments, a new study suggests that cytoreductive nephrectomy (CN) will not alter survival of patients with metastatic renal cell carcinoma (mRCC) with a short life expectancy ( Read More ›